Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation

详细信息    查看全文

• 作者：Takeshi Kondo (1) (2)
  Atsushi Yasumoto (1) (3)
  Kotaro Arita (1) (3)
  Jun-ichi Sugita (1) (3)
  Akio Shigematsu (1) (3)
  Kohei Okada (1) (2)
  Mutsumi Takahata (1) (2)
  Masahiro Onozawa (1) (2)
  Kaoru Kahata (1) (2)
  Yukari Takeda (1) (4)
  Masato Obara (1) (4)
  Satoshi Yamamoto (1) (4)
  Tomoyuki Endo (1) (4)
  Mitsufumi Nishio (1) (4)
  Norihiro Sato (1) (4)
  Junji Tanaka (1) (3)
  Satoshi Hashino (1) (2)
  Takao Koike (4)
  Masahiro Asaka (2)
  Masahiro Imamura (1) (3)
  
• 关键词：AML ; Favorable karyotype ; RIST
• 刊名：International Journal of Hematology
• 出版年：2010
• 出版时间：March 2010
• 年：2010
• 卷：91
• 期：2
• 页码：310-321
• 全文大小：393KB
• 参考文献：1. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69-9. CrossRef
  2. Lodewyck T, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. Blood Rev. 2008;22(6):293-02. CrossRef
  3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322-3.
  4. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-3.
  5. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995;85(5):1202-.
  6. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, et al. Early allogenic stem-cell transplantation with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol. 2005;23(30):7676-4. CrossRef
  7. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogenic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission. Cancer. 2005;103(8):1652-. CrossRef
  8. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997;90(8):2931-.
  9. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110(1):409-7. CrossRef
  10. Hamaki T, Kami M, Kim SW, Onishi Y, Kishi Y, Murashige N, et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone Marrow Transplant. 2004;33(9):891-00. CrossRef
  11. Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003;21(16):3060-. CrossRef
  12. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21(8):1480-. CrossRef
  13. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24(3):444-3. CrossRef
  14. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2008;14(5):568-5. CrossRef
  15. Ooi J, Iseki T, Takahashi S, Tomonari A, Takasugi K, Uchiyama M, et al. Unrelated cord blood transplantation after myeloablative conditioning for adult patients with refractory anemia. Int J Hematol. 2005;81(5):424-. CrossRef
  16. Sugita J, Tanaka J, Hashimoto A, Shiratori S, Yasumoto A, Wakasa K, et al. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation. Ann Hematol. 2008;87(12):1003-. CrossRef
  17. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99(6):2255-. CrossRef
  18. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-. CrossRef
  19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-.
  20. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250-.
  21. Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol. 2008;26(30):4940-. CrossRef
  22. Kasai M, Kiyama Y, Kawamura A. Application of peripheral blood stem cells (PBSC) mobilized by recombinant human granulocyte colony stimulating factor for allogeneic PBSC transplantation and the comparison of allogeneic PBSC transplantation and bone marrow transplantation. Transfus Apher Sci. 2002;26(2):121-. CrossRef
  23. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood. 2003;101(11):4233-4. CrossRef
  24. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531-.
  25. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-3.
  26. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-00. CrossRef
  27. Schmid C, Labopin M, Nagler A, Bornh?user M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938-5. CrossRef
  28. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11(4):1416-4. CrossRef
  29. Schlenk RF, D?hner K, Krauter J, Fr?hling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-8. CrossRef
  30. Bornh?user M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. AML SHG 96 study group. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007;109(5):2264-. CrossRef
  
• 作者单位：Takeshi Kondo (1) (2)
  Atsushi Yasumoto (1) (3)
  Kotaro Arita (1) (3)
  Jun-ichi Sugita (1) (3)
  Akio Shigematsu (1) (3)
  Kohei Okada (1) (2)
  Mutsumi Takahata (1) (2)
  Masahiro Onozawa (1) (2)
  Kaoru Kahata (1) (2)
  Yukari Takeda (1) (4)
  Masato Obara (1) (4)
  Satoshi Yamamoto (1) (4)
  Tomoyuki Endo (1) (4)
  Mitsufumi Nishio (1) (4)
  Norihiro Sato (1) (4)
  Junji Tanaka (1) (3)
  Satoshi Hashino (1) (2)
  Takao Koike (4)
  Masahiro Asaka (2)
  Masahiro Imamura (1) (3)
  
  1. Stem Cell Transplantation Center, Hokkaido University Hospital, Kita 14 Nishi 5, Kita-ku, Sapporo, 060-8648, Japan
  2. Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  3. Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  4. Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  

文摘

Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy. If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option. Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks. The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics. In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group. Both the 3-year OS and RFS rates were 81% in the conventional stem cell transplantation (CST) group. The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group. None of the patients died within 90?days after RIST. Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST. Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.